El interés en corto de Apyx Medical da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Apyx Medical. Los datos de interés en corto se actualizan cada dos semanas.

Apyx Medical (NASDAQ:APYX) Bolsa, Informe de interés en corto

Apyx Medical

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Bovie Medical

Apyx Medical Corp

Truist Securities analyst Neal Dingmann maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and raises the price target from $33 to $37.

News

Price Target

Analyst Ratings

CTRA

Truist Securities Maintains Buy on Coterra Energy, Raises Price Target to $37

<ul>
<li>NVDA</li>
<li>AMD</li>
<li>TSLA</li>
<li>MSTR</li>
<li>MRNA</li>
<li>$BTC</li>
<li>DJT</li>
<li>GAP</li>
<li>QQQ</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

$BTC

AAPL

MRNA

MSTR

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of January 13, 2025 (Via Swaggy Stocks)

Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged on Monday after the company announced business updates and progress <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/ac42940864/moderna-provides-business-and-pipeline-updates-at-43rd-annual-j-p-morgan-healthcare-conference" rel="noreferrer noopener">across its pipeline</a>. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.
The company will present at the 43rd&nbsp;Annual J.P. Morgan Healthcare Conference.
In September, Moderna unveiled key updates at its annual R&amp;D Day by reducing annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40863528/moderna-faces-analyst-downgrades-amid-revised-r-d-restructured-strategy-and-delayed" rel="noreferrer noopener">ten prioritized products</a>.
The company expects R&amp;D expenses to fall from $4.8 billion in 2024E to $3.6 billion—$3.8 billion in 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
The strategy, expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years.
In fiscal year 2024,&nbsp;Moderna achieved preliminary product sales of approximately $3 billion-3.1 billion, comprising $1.7 billion in the U.S. and $1.3 to 1.4 billion in the rest of the World.
This includes more than $3 billion in Spikevax sales and minimal sales from mRESVIA, its RSV Vaccine. Cash, cash equivalents, and investments at year-end 2024 were approximately $9.5 billion.
Moderna is accelerating and expanding its previous cost efficiency and prioritization programs and now projects cash cost reductions of $1.0 billion in 2025.
The company expects an additional $0.5 billion in potential cash cost savings in 2026. In September, the company announced its plans to reduce annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.
Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025 compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.95 billion</a>, mostly in the second half of the year, primarily due to Spikevax and mRESVIA vaccine sales. Earlier, Moderna projected revenues of $2.5 to $3.5 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">by 2025</a>.
The company expects to end 2025 with approximately $6.0 billion in cash and investments.
Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41854205/modernas-q3-earnings-beat-overshadowed-by-vaccine-demand-slowdown-and-market-share-concerns-analysts-warn" rel="noreferrer noopener">consensus of $1.25 billion</a>.
The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.
Price Action: At last check on Monday, MRNA stock was down 19.20% to $34.13.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42939311/wayfair-expands-google-cloud-partnership-to-tap-ai-for-cost-cuts-and-efficiency" target="_blank" rel="noreferrer noopener">Wayfair Expands Google Cloud Partnership To Tap AI For Cost Cuts And Efficiency</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Biotech

Large Cap

Guidance

Health Care

Movers

General

Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives

Contracts

FRGT

Freight Technologies Renews Logistics Services Contract With Kimberly-Clark de México For Additional Two Years

Barclays analyst Benjamin Budish maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and lowers the price target from $199 to $192.

Barclays Maintains Equal-Weight on Blackstone, Lowers Price Target to $192

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has dipped below $91,000, a move that aligns with historical post-halving patterns, according to <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42850002/bitcoin-dumps-below-99000-what-does-technical-analysis-say">prominent technical analysts</a>.
<h2 class="wp-block-heading">How Long Will Bitcoin's Consolidation Last?</h2>
Technical analyst Kevin highlighted that Bitcoin's 3-day price chart and the Moving Average Convergence Divergence (MACD) indicator have been reliable for tracking bull market trends.
Historical data shows that MACD downside crosses often precede consolidation periods lasting 30 to 174 days. Kevin <a href="https://x.com/Kev_Capital_TA/status/1878571595406389355">points</a> out a potential cyclical pattern:
<ul>
<li>Previous consolidations: 164, 30 and 174 days.</li>
<li>Current consolidation: 24 days so far, suggesting 35-40 days of range-bound trading before a breakout.</li>
</ul>
In another tweet, Kevin highlighted that Bitcoin faces substantial liquidity blocks between $86,000 to $90,000 and $104,000, suggesting possible sweeps in both directions that could cause choppy price action for the month.
Macro caution remains prudent until USDT Dominance breaks below 3.7% mark and BTC surpasses $108,000. 
Altcoins require careful risk management, particularly for traders. 
For long-term holders from bear market lows, patience and awaiting further data are key strategies.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42919731/bitcoin-to-bounce-back-in-q1-but-beware-20-corrections-analysts-warn">Bitcoin To Bounce Back In Q1 But Beware 20% Corrections, Analysts Warn</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Lets be realistic here. We have massive liquidity blocks in both directions from 86K to 90K all the way to 104K. The most logical thing I can say is we likely sweep all of it and continue to chop up and down for the rest of the month. I will continue to be macro cautious about… <a href="https://t.co/FluYcCW0uM">pic.twitter.com/FluYcCW0uM</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1878599887530434736?ref_src=twsrc%5Etfw">January 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What's Next: Adam, a prominent whale trader, <a href="https://x.com/abetrade/status/1878420611304706349">analyzed</a> weekend trends, predicting downside price "chop" through the end of the month. 
He highlighted the following key insights:
<ul>
<li>CME data: Non-reportable trades are heavily short—a pattern historically followed by rallies.</li>
<li>Seasonality: A weak January could lead to a strong February.</li>
<li>Spot data: Sell-heavy order books and clustered open interest suggest patience is needed.</li>
</ul>
For a long position, the ideal setup includes an open interest drop, increased spot demand and alignment with a high-volume node at a reasonable price action level. 
While the market trades within the range&#8217;s point of control, patience is critical, as the focus is on trading at extremes when markets are out of balance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bitcoin Down 8% In A Week: What Does Technical Analysis Say?

Cantor Fitzgerald analyst Li Watsek reiterates IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Overweight to Overweight.

Reiteration

IDYA

Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients
CTAs submitted for Phase 1 INLIGHT clinical trial of WVE-007, a novel, long-acting, muscle-sparing GalNAc-siRNA approach for obesity targeting INHBE grounded in human genetics; proof-of-concept clinical data expected in 2025
Pioneering entirely new therapeutic field of RNA editing and building on positive WVE-006 proof-of mechanism clinical data; expect multidose AATD data, new preclinical data from hepatic and extra-hepatic RNA editing programs and candidate selections in 2025
Expect feedback from regulators and 48-week FORWARD-53 data for WVE-N531 in DMD in 1Q 2025; positive interim data demonstrated highly consistent dystrophin expression and best-in-class muscle delivery
Advancing WVE-003 – only allele-selective treatment for HD; planning underway for potentially registrational Phase 2/3 study with caudate atrophy as a primary endpoint and IND submission expected 2H 2025
Well-capitalized with expected runway into 2027

Wave Life Sciences Announces 2025 Plans, Phase 1 INLIGHT Trial For Obesity Target WVE-007; RNA Editing Advancements With WVE-006; Regulatory Feedback And 48-Week Data For WVE-N531 In DMD Expected Q1 2025; Phase 2/3 Study For HD Treatment WVE-003 In Planning; Capital Runway To 2027

Ming Shing Group Holdings Limited (the "Company" or "Ming Shing") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>), a Hong Kong-based company mainly engaged in wet trades works whose mission it is to become the leading wet trades works service provider in Hong Kong, announces a significant update in its business development.
Ming Shing is pleased to announce that its wholly-owned Hong Kong subsidiary, Lead Benefit (HK) Limited ("Lead Benefit"), purchased 500 Bitcoins at an average price of US$94,375 per Bitcoin on January 9, 2025, with a total investment of approximately US$47 million. Lead Benefit was incorporated on December 23, 2024, with Lead Benefit International Limited, as its sole shareholder. Lead Benefit International Limited, a BVI business company, was incorporated on December 9, 2024, with Ming Shing as its sole shareholder. Ming Shing intends to use its idle funds to purchase Bitcoins as short-term investment to capture the potential appreciation of Bitcoin and increase its assets. The Company considers that Bitcoin market is highly liquid and the Bitcoins can be easily disposed to fund the Company's wet trade works business, if required.

Markets

Ming Shing Unit Lead Benefit Buys 500 Bitcoins At $94,375 Each, $47M Total, For Short-Term Investment To Boost Assets

EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) has outperformed the market over the past 5 years by 31.21% on an annualized basis producing an average annual return of 43.04%. Currently, EQT has a market capitalization of $29.41 billion. 
Buying $100 In EQT: If an investor had bought $100 of EQT stock 5 years ago, it would be worth $577.08 today based on a price of $49.29 for EQT at the time of writing.
<h3>EQT's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736778608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Offerings

BHAT

Blue Hat Prices $4.3M Registered Direct Offering Of 77,989,800 Shares At $0.055/Share

Cantor Fitzgerald analyst Ross Osborn reiterates Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) with a Overweight and maintains $8 price target.

Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $8 Price Target

<ul>
<li>More patients treated with ZTlido&#xAE; saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).</li>
<li>Of all study patients reporting a decrease in opioid use, significantly more in the ZTlido&#xAE; group experienced a 20% or greater reduction in opioid use, compared with those treated with 5% lidocaine patch (21.3% vs. 13.4%; P=0.0008).</li>
<li>Patients on ZTlido&#xAE; had a non-significant change in their baseline opioid use (+3.1%; P=0.146), while those using the 5% patch experienced a significant increase in opioid use from baseline (+42.9%; P&lt;0.001). &nbsp;</li>
</ul>
PALO ALTO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, today announced that Pain Medicine News published retrospective claims data on ZTlido&#xAE; vs. lidocaine 5% patch.
Pain Medicine News, the premier trade publication in the pain management space, published decreased opioid utilization demonstrated with ZTlido&#xAE; (lidocaine topical system 1.8%) in the magazine's December edition. The article concluded that retrospective claims data showed that Scilex Pharmaceuticals' flagship product, the branded ZTlido&#xAE; lidocaine patch, was associated with less use of opioid analgesics in patients with neuropathic pain compared with the 5% lidocaine patch (generic). The researchers looked at claims with a diagnosis of neuropathic pain (postherpetic neuralgia, diabetic peripheral neuropathy or low back pain) in the Optum Claims database from May 1, 2018, to Sept. 30, 2023.
Among the key conclusions were that:
<ul>
<li>More patients treated with ZTlido&#xAE; saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).</li>
<li>Of all study patients reporting a decrease in opioid use, significantly more in the ZTlido&#xAE; group experienced a 20% or greater reduction in opioid use, compared with those treated with 5% lidocaine patch (21.3% vs. 13.4%; P=0.0008).</li>
<li>Patients on ZTlido&#xAE; had a non-significant change in their baseline opioid use (+3.1%; P=0.146), while those using the 5% patch experienced a significant increase in opioid use from baseline (+42.9%; P&lt;0.001).</li>
</ul>

SCLX

Scilex Announces ZTlido Shows 51.9% Decrease In Opioid Use Compared To 45.5% With 5% Lidocaine Patch; 21.3% Achieve 20% Opioid Reduction Vs. 13.4% With Lidocaine; Non-Significant Opioid Use Change With ZTlido Vs. Significant Increase With 5% Patch

Truist Securities analyst Neal Dingmann maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Buy and raises the price target from $138 to $139.

Truist Securities Maintains Buy on ConocoPhillips, Raises Price Target to $139

GWAV

Greenwave Technology Solutions Announces $4M Offering Priced at Market; 7,544,323 Common Shares At $0.5302/Share

Crypto
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42942291/exclusive-bitcoin-tumbling-but-bull-market-top-isnt-in-yet-experts-say">Bitcoin Tumbling, But Bull Market Top Isn&#8217;t In Yet, Experts Say</a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42941143/mstr-stock-down-over-4-in-pre-market-after-michael-saylors-10th-consecutive-week-of-bitcoin-tracker-update-hinting-at-impending-btc-purchase">MSTR Stock Down Over 4% In Monday Pre-Market After Michael Saylor&#8217;s 10th Consecutive Week Of Bitcoin Tracker Update, Hinting At Impending BTC Purchase</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940555/bitcoin-slides-to-91000-ahead-of-upcoming-key-inflation-data">Bitcoin Slides To $91,000 Ahead Of Upcoming Key Inflation Data</a></li>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42938954/michael-saylors-microstrategy-faces-risk-if-mstrs-0-convertible-bond-lenders-recall-non-recourse-loans-due-to-covenant-breach-heres-what-it-means-for-investors">Michael Saylor&#8217;s MicroStrategy Faces Risk If MSTR&#8217;s 0% Convertible Bond Lenders Recall Non-Recourse Loans Due To Covenant Breach: Here&#8217;s What It Means For Investors</a></li>
<li><a href="https://www.benzinga.com/25/01/42937216/bitcoin-ethereum-lost-way-last-week-but-xrp">Bitcoin, Ethereum Lost Way But XRP Made Promising Headway — Here Are The Best Performers From Last Week</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42937173/ethereum-whale-offloads-33-million-in-eth-at-a-loss-as-crypto-sinks-11-in-a-week-this-is-what-indicators-suggest">Ethereum Whale Offloads $33 Million In ETH At A Loss As Crypto Sinks 11% In A Week — This Is What Indicators Suggest</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a></li>
<li><a href="https://www.benzinga.com/25/01/42936775/bitcoin-ethereum-dogecoin-rise-as-greed-sentiment-takes-over-top-analyst-says-breaking-this-resistance-level-could-be-pivotal-for-btc">Bitcoin, Ethereum, Dogecoin Rise As &#8216;Greed&#8217; Sentiment Takes Over: Top Analyst Says Breaking This Resistance Level Could Be &#8216;Pivotal&#8217; For BTC</a></li>
</ul>
US Markets­­­­­­­­
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42944934/wall-street-slashes-interest-rate-cut-bets-after-jobs-data-are-hikes-back-on-the-table">Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?</a></li>
<li><a href="https://www.benzinga.com/25/01/42940228/us-stocks-to-open-lower-as-index-futures-decline-analysts-see-a-buying-opportunity">US Stock Futures Indicate Lower Opening On Monday After Last Week&#8217;s Steep Fall: Analyst Says It&#8217;s A &#8216;Buying Opportunity,&#8217; But Market May Dip Further If This Happens</a></li>
<li><a href="https://www.benzinga.com/25/01/42939219/dow-tumbles-around-700-points-following-jobs-data-investor-sentiment-dips-further-fear-greed-index-remains-in-fear-zone">Dow Tumbles Around 700 Points Following Jobs Data, Investor Sentiment Dips Further: Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>
World Politics
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42938329/us-reportedly-probes-barriers-subsidies-and-unfair-trade-practices-by-china-in-global-shipbuilding-as-trump-tariff-threat-looms">US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms</a></li>
<li><a href="https://www.benzinga.com/news/25/01/42938083/justin-trudeau-says-canada-is-ready-to-respond-with-tariffs-as-necessary-amid-potential-trump-trade-war">Justin Trudeau Says Canada Is &#8216;Ready To Respond With Tariffs As Necessary&#8217; Amid Potential Trump Trade War</a></li>
<li><a href="https://www.benzinga.com/25/01/42937761/singapore-restricts-residents-from-using-prediction-platform-polymarket-over-gambling-law-violation">Singapore Cracks Down On Polymarket: Regulator Issues Warning Against &#8216;Illegal Gambling&#8217;</a></li>
</ul>
US Economy
<ul>
<li><a href="https://www.benzinga.com/25/01/42939374/as-bond-yields-near-the-crucial-5-mark-last-seen-briefly-in-2023-and-global-financial-crisis-this-analyst-says-market-appears-to-be-overreacting">US Treasury Yields Near Crucial 5% Mark Last Seen During 2008 Global Financial Crisis, But Analyst Dismisses Fears, Says &#8216;Market Appears To Be Overreacting&#8217;</a></li>
</ul>
World Economy
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/01/42941223/chinas-coal-consumption-at-new-highs-as-real-estate-crisis-fails-to-slow-energy-demands">China&#8217;s Coal Consumption At New Highs, As Real Estate Crisis Fails To Slow Energy Demands</a></li>
<li><a href="https://www.benzinga.com/25/01/42939868/asia-and-europe-markets-in-red-lower-crude-oil-gains-dollar-strengthens-global-markets-today-while-us-slept.">Asia And Europe Markets Fall, Dollar Hits New High &#8211; Global Markets Today While US Slept</a></li>
</ul>
Tech
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/42941939/nvidia-down-3-amd-falls-2-after-white-house-imposes-new-ai-chip-export-restrictions">Nvidia Down 3%, AMD Falls 2% After White House Imposes New AI Chip Export Restrictions</a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42939766/quantum-computing-stocks-tumble-after-mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-practical-comments-qubt-down-9-rgti-falls-16-and-ionq-loses-15">Quantum Computing Stocks Tumble After Mark Zuckerberg Backs Nvidia CEO Jensen Huang&#8217;s &#8216;Practical&#8217; Comments: QUBT Down 9%, RGTI Falls 16% And IONQ Loses 15%</a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42937107/mark-zuckerberg-criticizes-apple-for-stagnation-highlighting-years-long-rivalry-with-tim-cook-heres-the-backstory">Mark Zuckerberg Criticizes Apple For Stagnation, Highlighting Years-Long Rivalry With Tim Cook: Here&#8217;s The Backstory</a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42936751/mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-view-on-quantum-computing-its-still-quite-a-ways-off">Mark Zuckerberg Backs Nvidia CEO Jensen Huang&#8217;s View On Quantum Computing: &#8216;It&#8217;s Still Quite A Ways Off&#8217;</a></li>
<li><a href="https://www.benzinga.com/news/25/01/42936206/i-dont-need-billions-you-should-know-when-enough-is-enough-craig-from-craigslist-says-he-rejected-billions-to-redesign-the-platform">&#8216;I Don&#8217;t Need Billions. You Should Know When Enough Is Enough&#8217; – Craig From Craigslist Says He Rejected Billions To Redesign The Platform</a></li>
</ul>
Electric Vehicle
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42937389/tesla-hikes-model-3-y-prices-in-canada-by-c1000-after-announcing-price-increase-in-china">Tesla Hikes Model 3, Y Prices In Canada By C$1000 After Announcing Price Increase In China</a></li>
</ul>
Consumer
<ul>
<li><a href="https://www.benzinga.com/25/01/42945266/why-department-store-chain-macys-stocks-are-sliding-on-monday-premarket">Why Is Department Store Chain Macy&#8217;s Stock Sliding Today?</a></li>
<li><a href="https://www.benzinga.com/25/01/42939311/wayfair-expands-google-cloud-partnership-to-tap-ai-for-cost-cuts-and-efficiency">Wayfair Expands Google Cloud Partnership To Tap AI For Cost Cuts And Efficiency</a></li>
<li><a href="https://www.benzinga.com/25/01/42938610/ford-sold-more-electric-mustangs-than-gas-mustangs-in-2024">Ford Sold More Electric Mustangs Than Gas Mustangs In 2024</a></li>
</ul>
Communication
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/01/42938506/elon-musk-urges-mark-zuckerberg-to-release-facebook-files-calls-it-good-after-meta-adopts-xs-community-notes-like-feature">Elon Musk Urges Mark Zuckerberg To Release Facebook Files, Calls It &#8216;Good&#8217; After Meta Adopts X&#8217;s Community Notes-Like Feature</a></li>
</ul>
Industrial
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42942232/boeing-stock-wiped-out-47-of-investor-wealth-over-the-last-5-years-amid-multiple-issues-now-this-expert-suggests-a-breakup-could-benefit-the-airplane-maker">Boeing Stock Wiped Out 47% Of Investor Wealth Over The Last 5 Years Amid Multiple Issues — Now, This Expert Suggests A Breakup Could Benefit The Airplane Maker</a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42938119/lockheed-martin-donates-1m-to-trumps-inaugural-committee-as-speculation-grows-over-elon-musk-led-doge-crackdown-on-traditional-defense-contracts">Lockheed Martin Donates $1M To Trump&#8217;s Inaugural Committee As Speculation Grows Over Elon Musk-Led DOGE Crackdown On Traditional Defense Contracts</a></li>
</ul>
Healthcare
<ul>
<li><a href="https://www.benzinga.com/25/01/42939353/why-sage-therapeutics-shares-are-trading-higher-by-over-34-here-are-20-stocks-moving-premarket">Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket</a></li>
</ul>
Financial
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42942837/hhh-climbs-11-after-bill-ackmans-pershing-square-offers-to-buy-remaining-stake">Howard Hughes Stock Jumps 11% In Pre Market After Bill Ackman&#8217;s Pershing Square Offers $85 Per Share To Buy Remaining Stake</a></li>
<li><a href="https://www.benzinga.com/25/01/42939865/bank-of-america-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Bank of America Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
General
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940832/jamie-dimon-says-hes-not-against-blockchains-but-trades-guns-on-bitcoin-again-it-has-no-intrinsic-value-i-just-dont-feel-great-about">Jamie Dimon Says He&#8217;s Not Against Blockchains But Trades Guns On Bitcoin Again—It Has No Intrinsic Value: &#8216;I Just Don&#8217;t Feel Great About&#8230;&#8217;</a></li>
<li><a href="https://www.benzinga.com/general/space/25/01/42939786/despite-elon-musks-feud-with-gavin-newsom-tesla-rolls-out-support-for-california-amid-wildfires-with-cybertrucks-starlink-and-megapack-chargers">Despite Elon Musk&#8217;s Feud With Gavin Newsom, Tesla Rolls Out Support For California Amid Wildfires With Cybertrucks, Starlink And Megapack Chargers</a></li>
</ul>
Space
<ul>
<li><a href="https://www.benzinga.com/25/01/42939090/jeff-bezos-blue-origin-delays-new-glenn-launch-after-identifying-issue">Jeff Bezos&#8217; Blue Origin Scraps New Glenn Liftoff Due To Vehicle Subsystem Issue, Next Launch Date Unclear</a></li>
<li><a href="https://www.benzinga.com/general/space/25/01/42937833/elon-musks-spacex-delays-starship-7th-test-flight-to-wednesday">Elon Musk&#8217;s SpaceX Delays Starship 7th Test Flight To Wednesday</a></li>
</ul>
Image via Shutterstock

$ETH

Bitcoin Drops To $91,000 Amid Inflation Data Concerns; Dow Sheds 700 Points After Jobs Report, Sentiment Worsens; Greed Index Stays In 'Fear' Zone; Quantum Computing Stocks Fall As Zuckerberg Supports Nvidia's Jensen – Top Headlines While the U.S. Slept

<ul>
<li>This option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga&#x2122;, with a maximum value of $704 million
<ul>
<li>Program progress and performance triggers $16.7 million contract option</li>
</ul>
</li>
</ul>

Emergent BioSolutions Receives $16.7M Contract Option To Continue Development Collaboration With BARDA On Ebanga Treatment For Ebola

Barclays analyst Benjamin Budish maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and lowers the price target from $1220 to $1160.

Barclays Maintains Overweight on BlackRock, Lowers Price Target to $1160

MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has expanded its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holdings by purchasing an additional 2,530 bitcoins for approximately $243 million, <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42870343/what-microstrategys-declining-net-asset-value-premium-really-means-for-bitcoin">averaging $95,972 per coin</a>, according to an SEC filing.
This acquisition was funded through the sale of 710,425 shares of the company&#8217;s class A common stock, conducted between January 6 and January 12, 2025, under a previously established Sales Agreement, the <a href="https://www.sec.gov/Archives/edgar/data/1050446/000119312525005000/d884652d8k.htm">filing</a> states.
The share sales generated net proceeds of about $243 million. 
As of Jan.12, approximately $6.53 billion worth of shares remain available for future issuance and sale under this agreement.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42942291/exclusive-bitcoin-tumbling-but-bull-market-top-isnt-in-yet-experts-say">EXCLUSIVE: Bitcoin Tumbling, But Bull Market Top Isn&#8217;t In Yet, Experts Say</a>
With this latest purchase, MicroStrategy and its subsidiaries now hold a total of approximately 450,000 Bitcoin, acquired at an aggregate cost of around $28.2 billion, which equates to an average purchase price of $62,691 per Bitcoin, inclusive of fees and expenses.
The company also reported a BTC Yield of 0.32% for the period from Jan. 1 to Jan. 12, 2025.
BTC Yield is a key performance indicator that measures the percentage change in the ratio between MicroStrategy&#8217;s Bitcoin holdings and its Assumed Diluted Shares Outstanding over a specific period.
MicroStrategy continues to utilize its at-the-market share offering program to fund its bitcoin acquisition strategy, apparently reinforcing its commitment to Bitcoin as a primary treasury reserve asset.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940555/bitcoin-slides-to-91000-ahead-of-upcoming-key-inflation-data">Bitcoin Slides To $91,000 Ahead Of Upcoming Key Inflation Data</a></li>
</ul>
Image: Shutterstock

MicroStrategy Acquires 2,530 Bitcoin For $243M, Reaching 450,000 BTC In Total Holdings

Eco Wave Power Global AB (publ) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>) ("Eco Wave Power" or the "Company"), a leader in the onshore wave energy technology sector, is pleased to announce that it has engaged MOQ Engineering ("MOQ"), a renowned Portuguese engineering firm, to perform the final design and load calculations for its pioneering wave energy project in Porto, Portugal. This work represents a key milestone in the project's advancement and positions the project for a targeted launch during 2026.
The project is a part of a 20 MW Concession Agreement entered into with Administração dos Portos do Douro, Leixões e Viana do Castelo, S.A. (APDL), which is located in the city of Porto. It will feature Eco Wave Power's proprietary wave energy technology and includes a first-of-its-kind underwater wave energy museum and education centre, set to be housed in "The Gallery" – the room underneath the breakwater where the Company's energy conversion equipment will be installed. The innovative project aligns with Portugal's renewable energy goals, aiming to generate 85% of its electricity from renewable sources by 2030.
The collaboration with&nbsp;MOQ will focus on delivering the final civil engineering design and detailed load calculations for the floaters, which are key components of Eco Wave Power's innovative wave energy conversion system. These calculations and designs will be ensuring the safe and efficient installation of the floaters on the marine structure at the project site. This phase of work is scheduled for completion by February 2025.
Upon completion of MOQ's scope of work, Eco Wave Power will submit the full execution project, including all finalized engineering and technical specifications, to APDL. The approval of the execution project by APDL will mark the transition to the next phase of the project: the production of the floaters and accompanying structural components.
The first MW-scale wave energy project in Porto will demonstrate significant energy production from ocean waves and serve as a critical step towards the commercialization of Eco Wave Power's technology globally. In addition to its environmental impact, the project is expected to reduce the port's carbon footprint, create new jobs, and contribute to Portugal's innovative renewable energy industry.
Eco Wave Power is also advancing additional projects globally, including upcoming initiatives in Taiwan and the Port of Los Angeles. Moreover, the Company plans to announce new projects in additional countries, further expanding its footprint in the wave energy sector and reinforcing its position as a leader in renewable energy innovation.

Global

WAVE

Eco Wave Power Engages MOQ For Wave Energy Project Design In Porto, Portugal; Part Of 20 MW Concession With APDL, Featuring Underwater Energy Museum; Targeted 2026 Launch

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apyx Medical (APYX – Research Report) and Delcath Sy...

Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX) and Delcath Systems (DCTH)

Apyx Medical GAAP EPS of -$0.14, revenue of $11.5M

Apyx Medical looks to raise $7M through direct offering

Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript

Apyx Medical ( ($APYX) ) has released its Q3 earnings. Here is a breakdown of the information Apyx Medical presented to its investors. Apyx Medical...

Apyx Medical Reports Q3 Results and Restructuring

Craig-Hallum lowered the firm's price target on Apyx Medical (APYX) to $4 from $6 and keeps a Buy rating on the shares. In a traditionally softer q...

Apyx Medical price target lowered to $4 from $6 at Craig-Hallum

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Apyx Medical (APYX – Research Report). The company's shar...

Apyx Medical (APYX) Receives a Hold from JMP Securities

Apyx Medical (APYX) announces it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for the AYON Body Contourin...

Apyx Medical submits 510k premarket notification to FDA for AYON BCS

BTIG analyst Sam Eiber reiterated a Hold rating on Apyx Medical (APYX – Research Report) today. The company's shares closed last Friday at $1.66. T...

BTIG Remains a Hold on Apyx Medical (APYX)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Apyx Medical (APYX – Research Report) today. The company's shares closed last Friday at...

Craig-Hallum Remains a Buy on Apyx Medical (APYX)

APYX

DCTH

Press Releases

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures

Renuvion Named #1 Trusted Body Contouring Technology by Doctors*

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Earnings

Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook

IPOs

Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

HeartBeam

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Apyx Medical

Interés en corto

Apyx Medical (NASDAQ:APYX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL